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Although previous authors have reported single data point, yearly changes in respiratory func-
tion have not been examined in combined pulmonary fibrosis and emphysema (CPFE). To quan-
tify the annual changes in respiratory function of patients with CPFE and to examine the
difference in survival between CPFE patients and patients with idiopathic pulmonary fibrosis
without emphysema (IPF alone), 26 patients with CPFE and 33 IPF alone patients, whose respi-
ratory function had been monitored for at least a year, were selected. The baseline of vital
capacity percent predicted (VC% pred) in CPFE patients was greater than that in IPF-alone
patients (86.6  24.0% vs. 72.8  19.4%, pZ 0.018). The annual decrease in VC% pred was
significantly less in CPFE patients than in IPF-alone patients (1.2  4.8% vs. 8.0 7.4%,
p< 0.001). Baseline ratio of forced expiratory volume in one second to forced vital capacity
(FEV1/FVC%) in CPFE patients was lower than that in IPF-alone patients (76.6  8.5% vs.
85.2  6.7%, p < 0.001). In the CPFE group, FEV1/FVC% tended to decrease with time
(0.5 2.2% per year), but, in contrast, it increased in IPF-alone patients (þ1.1 3.4% per
year) (pZ 0.036). Baseline of diffusing capacity percent predicted (DLco% pred) was signifi-
cantly lower in CPFE patients than in IPF-alone patients (45.3  15.0% vs. 60.7  19.8%,
pZ 0.003). The annual decrease in DLco% pred was lower in CPFE patients than in IPF-alone
patients (3.7  7.9% vs. 10.7  8.8%, pZ 0.042). There was no significant difference in
the survival duration between 26 CPFE and 33 IPF-alone patients according to KaplaneMeier
analysis.
Ventilatory and gas-exchange deterioration during the course of IPF became mild when
emphysema was coexistent.
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Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing
interstitial pneumonia with the histology of usual intersti-
tial pneumonia (UIP).1e3 Steroid treatment minimally
improves pulmonary function and the prognosis is poor.1,3e8
Combined pulmonary fibrosis and emphysema (CPFE) has
been described previously.9e13 Smoking is associated with
the pathogenesis and development of pulmonary emphy-
sema, especially emphysema of the upper lobes of the
lungs,14 and has been identified as a risk factor for IPF.3
Although the combination of pulmonary emphysema and
fibrosis may be incidental in smokers, recent studies have
identified common pathways of cellular and molecular
activation that result in different morphological and phys-
iological outcomes. Smad3 is considered a key molecule
linking fibrosis with emphysema.15 Smad3-null mice, defi-
cient in TGF-b signal transmission, are resistant to bleo-
mycin- and TGF-b-mediated fibrosis but spontaneously
develop age-related air-space enlargement, which is
consistent with emphysema, and lack the ability to repair
tissue damage appropriately.15 TNFa,16 IL-1b,17 MMP-12,18
VEGF,19,20 and PDGF21 have been reported to be responsible
for the pathogenesis and development of both pulmonary
fibrosis and emphysema.
In CPFE, the decrease in diffusing capacity (DLco) is
substantial because of the additive effect of emphysema
and fibrosis. A decrease in lung volume in IPF is associated
with decreased compliance and increased flow rates. An
increase in lung volume in emphysema is associated with
increased compliance and decreased flow rates due to
expiratory flow limitation and air trapping. When pulmo-
nary fibrosis and emphysema are coexistent, ventilatory
function appears normal because of their opposing
effects22 mentioned above. Previous authors have reported
single data point in CPFE, but yearly changes in respiratory
function have not been examined.
We retrospectively enrolled patients with IPF and
compared vital capacity (VC), the ratio of forced expiratory
volume in one second to forced vital capacity (FEV1/FVC%),
total lungcapacity (TLC), carbonmonoxidediffusingcapacity
(DLco), and DLco/VA (transfer factor) between patients with
CPFE and patients with IPF but no emphysema (IPF alone).
Time-dependent fluctuations in ventilatory and gas-
exchange functions in the two disorders are reported herein.
An additional aim of our study was to determine the
prognosis for IPF patients with or without emphysema.
KaplaneMeier survival curves were compared between the
two groups of patients.
Materials and methods
Patient population
We reviewed medical files of all patients admitted to the
Department of Respiratory Medicine at Fukuoka University
Hospital from 1988 to 2007 and identified those who were
diagnosed with IPF at discharge. Of this subset of patients,
55 who met the following criteria were classified as IPF
patients without emphysema (IPF-alone group): 1) presence
of dyspnea of insidious onset; 2) a computed tomography(CT) scan showing patterns compatible with IPF, including
bilateral reticular opacities and/or honeycombing of
a predominantly peripheral, subpleural, and basal location,
as main findings, as proposed by the American Thoracic
Society (ATS) and the European Respiratory Society (ERS),1
but no evidence of well-demarcated areas of low attenua-
tion typical of emphysema; 3) impaired ventilatory capacity
as indicated by measurements of VC or TLC and/or
impaired diffusing capacity (decreased DLco); and 4)
absence of known causes of pulmonary fibrosis such as
collagen vascular disease, hypersensitivity pneumonitis,
and drug-induced lung disease.
Thirty-two patients who met the following criteria were
categorized as CPFE patients: 1) as for criterion 1) for IPF-
alone patients; 2) a CT scan showing well-demarcated areas
of low attenuation typical of emphysema located predom-
inantly in the upper lung zones and patterns compatible
with IPF (as for IPF-alone patients); 3) as for criterion 3) for
IPF-alone patients; and 4) as for criterion 4) for IPF-alone
patients.
Among these patients, 33 IPF-alone and 26 CPFE patients
who had undergone repeated respiratory function tests for
at least a year were selected for further analysis.
The Fukuoka University Hospital review board approved
the study and waived the requirement for informed consent.
Clinical data
Records of clinical data such as sex, age, and smoking in
pack-years were reviewed to identify differences between
the characteristics of the CPFE and IPF-alone groups. The
duration of the follow-up period was estimated from the
interval between the first and last visits to our clinic or
between the first visit to our clinic and death. Death of the
patients who had left our hospital was determined by the
telephone call to their families or the next hospitals they
visited. If the patients were alive, the follow-up period was
from their first visit of our hospital to the time of the
telephone call.
Interstitial pneumonia pattern according
to chest CT
Chest CT patterns of interstitial pneumonia were divided
into two patterns with the reference to the classification by
Sumikawa et al.23; one was definite UIP pattern and the
other was the pattern consistent with UIP.
1) Definite UIP: The CT was classified as definite UIP when
CT scans showed honeycombing in a predominantly
peripheral and basal distribution.
2) Consistent with UIP: The CT was classified as consistent
with UIP when it demonstrated a reticular pattern in
a predominantly peripheral and basal distribution but
only minimal or no honeycombing, or when the extent
of honeycombing in the upper lobes was almost similar
to that in the lower lobes, but honeycombing was
peripherally distributed. The CT scan was also classified
as consistent with UIP when honeycombing dominantly
existed in the lower lobes, but it was distributed not
only in the peripheral zone but also in the inner zone.
Table 1 Clinical features of 26 CPFE and 33 IPF-alone
patients.
CPFE
(nZ 26)
IPF alone
(nZ 33)
p
values
Male/female 23/3 22/11 0.100a
Age at first visit 65.1 8.5 66.5 9.2 0.531b
Follow-up periods (years) 4.67 2.15 3.73 2.42 0.126b
Patients with/without
smoking history
24/2 25/8 0.183a
Pack-year for all patients 54.9 38.7 30.2 33.1 0.011b
Pack-year for patients
with smoking history
59.5 36.7
(nZ 24)
39.9 32.5
(nZ 25)
0.053b
Body mass index 24.0 3.4 22.0 3.4 0.027b
Patients with/without
steroid treatment
10/16 15/18 0.589a
Patients with
surgical lung biopsy
and/or autopsy
8 12 0.751a
Continuous values show means and standard deviations.
a Fisher’s exact test.
b unpaired t-test.
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Pulmonary emphysema detected by chest CT was catego-
rized as centrilobular, panlobular, or paraseptal.24
Respiratory function parameters
Forced expiratory volume in one second (FEV1) and VC were
measured using spirometry conducted with the patient in
a seated position. Results are expressed as absolute values
(mL) and as percentages of predicted values (% pred)
calculated using Baldwin’s formulae25 adjusted according to
sex, height, and age. TLC, functional reserve capacity (FRC),
residual volume (RV), and RV/TLC were measured using the
helium gas dilution method and DLco and DLco/VA (transfer
factor) were measured using the single-breath-holding
method.26 Predicted values for each lung volume parameter
were estimated using Grimby’s formula25 and predicted
values for DLco and DLco/VA were estimated using Burrows’
formula.27 These data were expressed as absolute values
(mL) and/or percentages of predicted values.
Baseline and follow-up respiratory function data
Respiratory function tests were repeated during the course
of the study. Baseline respiratory function was estimated
from the first tests conducted at our hospital. To estimate
the annual change in pulmonary function, we used data from
patients who had undergone pulmonary function tests at
least twice during a follow-up period of one year or more.
Annual changes in pulmonary function were estimated from
linear regressions, assuming time-dependency and linearity.
Survival
Survival curves were determined using the KaplaneMeier
method not only for the 26 CPFE and 33 IPF-alone patients
with repeated respiratory function tests but also for all
patients in this study (32 CPFE and 55 IPF-alone patients).
Statistical analysis
Numerical variables are expressed as means and standard
deviations. The baseline values and changes per year in VC,
FEV1/FVC%, TLC, FRC, RV, DLco, and DLco/VA of the CPFE
and IPF-alone groups were compared using unpaired t-test.
Categorical variables such as sex, smoking history, and
steroid treatment were evaluated using Fisher’s exact test.
Survival analysis was performed using the KaplaneMeier
method and the log-rank test. Null-hypothesis probability
values of <0.05 were considered significant.
Results
Patient characteristics
Patient characteristics of the 26 CPFE and 33 IPF-alone
patients are summarized in Table 1. The follow-up period
after the first visit did not differ significantly between the
CPFE and IPF-alone patients (4.67 2.15 years vs.
3.73 2.42 years, respectively, pZ 0.126).Eight patients in the IPF-alone group and two in the CPFE
group denied their smoking history. The pack-year for the
CPFE group (54.9 38.7) was significantly greater than that
for the IPF-alone group (30.2 33.1) (pZ 0.011). When
patients who had never smoked were excluded from the
analysis, the pack-year for the CPFE group (59.5 36.7)
was not significantly greater than that for the IPF-alone
group (39.9 32.5) (pZ 0.053).
The body mass index (BMI) of CPFE patients (24.0 3.4)
was significantly greater than that of IPF-alone patients
(22.0 3.4) (pZ 0.027).
There were no significant differences between CPFE and
IPF-alone patients in the number of patients who were
administered steroids or who were histologically diagnosed
by surgical lung biopsy and/or autopsy.
Interstitial pneumonia patterns according
to chest CT
As CT films were not available in three patients with IPF
alone and two with CPFE, we considered these patients as
those with UIP from the comments by radiologists in the
medical records, and they were not included in the IPF sub-
classification. After excluding patients with IPF alone or
CPFE pathologically confirmed by surgical lung biopsy and/
or autopsy and patients whose CT films were not available,
16 CPFE and 18 IPF-alone patients were categorized
according to the interstitial pneumonia patterns on chest
CT. Of the 16 CPFE patients, 13 were categorized as definite
UIP, and 3 were as consistent with UIP. Of the 18 IPF-alone
patients, 11 were categorized as definite UIP, and 7 were as
consistent with UIP.
Emphysema patterns according to chest CT
As the CT films of two CPFE patients were not available,
CPFE diagnosis was dependent on comments made by
1212 T. Akagi et al.radiologists in their medical records. These two patients
were not included in the emphysema sub-classification.
Thirteen of 24 patients had paraseptal emphysema as
the dominant pattern (Fig. 1) with centrilobular emphy-
sema as a minor component. One patient had paraseptal
emphysema alone without centrilobular emphysema. Ten
patients had centrilobular-dominant emphysema (Fig. 2)
with paraseptal emphysema as a minor component.
Respiratory function data
Baseline data
Both VC absolute volume and VC% pred were significantly
greater in the CPFE group (2823 844 mL and 86.6 24.0%)
than in the IPF-alone group (2220 768 mL and
72.8 19.4%) (pZ 0.006 and 0.018, respectively). FEV1/
FVC% in CPFE patients (76.6 8.5%) was significantly less
than in IPF-alone patients (85.2 6.7%) (p< 0.001). TLC
absolute volume was significantly greater in the CPFE group
(4236 1014 mL) than in the IPF-alone group
(3472 921 mL) (pZ 0.005). However, TLC% pred did not
differ significantly between the CPFE and IPF-alone groups
(78.2 17.4% vs. 70.0 16.4%, respectively, pZ 0.070).
Both DLco% pred and DLco/VA% pred were significantly
lower in the CPFE group (43.5 15.0% and 51.8 3.8%) than
in the IPF-alone group (60.7 19.8% and 80.1 23.2%)
(pZ 0.003 and p< 0.001, respectively) (Table 2).
Changes per year
The duration of the follow-up periods formeasurement of VC
in the CPFE (3.07 1.86 years) and IPF-alone groups
(2.48 1.14 years) was not significantly different between
the groups (pZ 0.139). During the follow-up period, VC was
measured 7.6 5.4 times in CPFE patients and 8.7 7.7
times in IPF-alone patients; there was no significant differ-
ence between the groups. The number of measurements of
lung volume parameters (TLC, FRC, and RV) during the
follow-up periods for the CPFE and IPF-alone groups were
6.1 3.6 and 6.2 3.3, respectively, without significant
difference. The number of measurements of DLco in CPFE
group (3.3 2.0) was smaller than that in IPF-alone group
(5.7 3.6), but not to a significant extent (pZ 0.054).
The annual decreases in both VC absolute volume and
VC% pred were significantly less in the CPFE group
(37 147 mL and 1.2 4.8%) than in the IPF-alone groupFigure 1 Chest CT of a 55-year-old man with paraseptal emphys
suggestive of paraseptal emphysema are evident in the bilateral
opacity with honeycombing was noted in the bilateral lower lobes(244 187 mL and 8.0 7.4%) (p< 0.001, in both
comparisons) (Table 3).
In the CPFE group, FEV1/FVC% tended to decrease with
time (0.5 2.2% per year). In contrast, FEV1/FVC% tended
to increase in patients with IPF alone (þ1.1 3.4% per
year) (pZ 0.036).
The annual decreases in both TLC absolute volume and
TLC% pred in the CPFE group (118 256 mL and
2.4 4.7%) were significantly less than those in the IPF-
alone group (296 138 mL and 6.0 3.1%) (pZ 0.014
and 0.011, respectively).
The annual decrease in DLco% pred in CPFE patients
(3.7 7.9%) was significantly less than in patients with IPF
alone (10.7 8.8%) (pZ 0.042). However, the decrease in
DLco/VA% pred per year in CPFE patients was not signifi-
cantly different from that in IPF-alone patients (Table 3).
Survival
When survival rate was compared between all CPFE and
IPF-alone patients in this study, patients with CPFE survived
longer than those with IPF alone, according to the Kaplane
Meier analysis, although the statistical significance was
marginal (pZ 0.050) (Fig. 3).
Of the 26 patients with CPFE, nine died of the disease,
11 died of other causes (six died of lung cancer), four lived,
and follow-up consultations for two were terminated
because we lost them after they left our hospital. Of the 33
patients with IPF alone, 19 died of the disease, three died
of lung cancer, seven lived, and follow-up consultations for
four were terminated because we lost them after they left
our hospital. When survival rate was compared between the
26 CPFE and the 33 IPF-alone patients, the difference was
not statistically significant (pZ 0.212) (Fig. 4).
Survival curves were also drawn and compared between
males and females, patients with or without steroid treat-
ment, and patients classified according to the median
values for BMI (23.1) or pack-year (37.5). These factors did
not affect survival rate.
Discussion
Technical advances in CT have facilitated the detection of
small, round, low-attenuation areas suggestive of emphy-
sema in the upper lung lobes. Chest radiographs do notema and definite UIP. Multiple round subpleural cystic changes
upper and lower lobes (panels a and b). Subpleural reticular
(panel b).
Figure 2 Chest CT of a 49-year-old man with centrilobular emphysema and pulmonary fibrosis consistent with UIP. Multiple round
areas lacking recognizable walls or with thin walls are evident in the left upper lobe, which is suggestive of centrilobular
emphysema (panel a). Subpleural reticular and ground-glass opacities were noted in the bilateral lower lobes, which were asso-
ciated with traction bronchiectasis in the left B8 (panel b).
Pulmonary fibrosis and coexistent emphysema 1213detect such areas. It is now known that cigarette smoking is
a risk factor for idiopathic pulmonary fibrosis28 as well as
pulmonary emphysema.
When emphysema is combined with pulmonary fibrosis,
emphysema may obscure ventilatory characteristics typical
of a restrictive disease. Lung volumes of CPFE patients may
be preserved whereas FEV1 and FEV1/FVC% may be similar
to those of normal subjects because the supervening
fibrosis prevents the early airway closure observed in
emphysema.
The baseline ventilatory capacity characteristics of the
CPFE group in our study were similar to those described by
others,12,13,22 viz., lung volumes were relatively well
preserved in CPFE patients compared with patients with IPF
alone, and FEV1/FVC% of CPFE patients appeared normal
but was significantly less than that of patients with IPF
alone. The baseline DLco in CPFE patients was also similar
to that reported in the literature. The decrease in DLco at
baseline was more advanced in CPFE patients than in
patients with IPF alone, probably because of the additive
effect of two disorders that both reduce diffusing capacity.
This report is the first to compare the yearly dynamics of
pulmonary function parameters of CPFE patients with thoseTable 2 Baseline respiratory function data.
CPFE
VC (absolute volume, mL) 2823 844 (nZ 26)
VC% pred 86.6 24.0 (nZ 26)
FEV1/FVC% 76.6 8.5 (nZ 26)
TLC (absolute volume, mL) 4236 1014 (nZ 25)
TLC% pred 78.2 17.4 (nZ 25)
FRC (absolute volume, mL) 2540 751 (nZ 25)
FRC% pred 78.3 18.9 (nZ 25)
RV (absolute volume, mL) 1476 494 (nZ 25)
RV% pred 74.6 22.6 (nZ 25)
DLco% pred 45.3 15.0 (nZ 23)
DLco/VA% pred 51.8 3.8 (nZ 23)
Data show means and standard deviations.
a unpaired t-test.of patients with IPF alone. The most salient results were: 1)
the rate of decrease of VC and TLC in CPFE patients was
significantly less than that of patients with IPF alone; 2)
although FEV1/FVC% in patients with IPF alone increased
gradually, it decreased in CPFE patients; and 3) the yearly
rate of decrease of DLco in CPFE patients was also signifi-
cantly less than that in patients with IPF alone. When
fibrosis and emphysema are coexistent, ventilatory
impairment is cancelled, resulting in normal-appearing lung
volume. In addition, yearly decrease in lung volume is
modest. Such a modest decline of ventilatory function
might palliate the deterioration of ventilation-perfusion
mismatch that is mainly responsible for the impaired DLco.
The prognosis of CPFE patients was better than that of
IPF-alone patients when all CPFE and IPF-alone patients
were included in the analysis. However, analysis of patients
whose respiratory function had been monitored for at least
one year showed no significant difference in the duration of
survival between the two groups. This was probably a result
of selection of patients who had survived long enough to
undergo repeated pulmonary function tests.
Schwartz et al. showed that a high FEV1/FVC% is asso-
ciated with an adverse prognosis in patients with IPF.29IPF alone p valuesa
2220 768 (nZ 33) 0.006
72.8 19.4 (nZ 33) 0.018
85.2 6.7 (nZ 33) <0.001
3472 921 (nZ 31) 0.005
70.0 16.4 (nZ 31) 0.070
2224 666 (nZ 31) 0.102
76.1 21.8 (nZ 31) 0.694
1364 384 (nZ 31) 0.340
76.1 26.7 (nZ 31) 0.825
60.7 19.8 (nZ 30) 0.003
80.1 23.2 (nZ 29) <0.001
Table 3 Changes per year in respiratory function data.
CPFE IPF alone p valuesa
VC (absolute volume, mL) 37 147 (nZ 26) 244 187 (nZ 33) <0.001
VC% pred 1.2 4.8 (nZ 26) 8.0 7.4 (nZ 33) <0.001
FEV1/FVC% 0.5 2.2 (nZ 26) þ1.1 3.4 (nZ 33) 0.036
TLC (absolute volume, mL) 118 256 (nZ 16) 296 138 (nZ 19) 0.014
TLC% pred 2.4 4.7 (nZ 16) 6.0 3.1 (nZ 19) 0.011
FRC (absolute volume, mL) 123 205 (nZ 16) 183 144 (nZ 19) 0.315
FRC% pred 5.6 8.2 (nZ 16) 7.2 6.4 (nZ 19) 0.538
RV (absolute volume, mL) 77 148 (nZ 16) 113 152 (nZ 19) 0.488
RV% pred 5.4 9.0 (nZ 16) 7.9 10.6 (nZ 19) 0.457
DLco% pred 3.7 7.9 (nZ 12) 10.7 8.8 (nZ 15) 0.042
DLco/VA% pred 4.1 9.4 (nZ 12) 7.3 11.7 (nZ 15) 0.457
Data show means and standard deviations.
a unpaired t-test.
1214 T. Akagi et al.However, the temporal relationship between FEV1/FVC%
and the survival of both groups in our study (data not
shown) appears inconsistent with their findings. As stated,
it is difficult to predict the prognosis of IPF simply from
changes in ventilatory impairment. Detection of coexistent
emphysema using CT is important to avoid making an
incorrect prognosis.
Paraseptal emphysema was frequently observed in CPFE
patients. Cottin et al.12 reported results similar to ours. It is
well known that centrilobular emphysema is smoking
related.30 Paraseptal emphysema appears to be peculiar to
smoking-induced CPFE. Further studies are warranted to
elucidate the etiology of paraseptal emphysema in CPFE.
Our study had several limitations. First, it was a retro-
spective study with a small sample size; additional
prospective studies with large sample sizes are warranted
to confirm our results. Second, diagnosis of CPFE and IPF
alone was mainly dependent on CT findings and less than
half of the diagnoses were validated by the results of
a surgical lung biopsy or an autopsy. Some patients with
chronic interstitial pneumonia other than UIP such as
fibrotic nonspecific interstitial pneumonia and respiratory
bronchiolitis-interstitial lung disease could be included inSurvival (years)
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Figure 3 KaplaneMeier survival curves for all patients
enrolled in this study. CPFE patients (thick line) survived longer
than patients with IPF alone (thin line), but the statistical
significance of the difference was marginal (pZ 0.050).our patient groups, especially in the ‘‘consistent with UIP’’
patient group. In addition, we did not analyze the rela-
tionship between the extent of emphysema or fibrosis and
functional impairment or survival. Third, the number of
measurements per patient used to estimate the linear
decrease per year in DLco and DLco/VA was less than that
used to estimate the linear decrease per year in VC and
TLC. DLco may be a better prognostic indicator of CPFE
than VC or TLC; the effects of two concurrent disorders on
gas-exchange capacity are additive whereas the effects of
two concurrent disorders on VC and TLC may cancel each
other out. The equation describing the temporal decrease
in DLco and DLco/VA would have been more accurate if
measurements had been obtained more frequently. More
frequent measurement of DLco and DLco/VA may reveal
a more significant difference in the temporal decrease
between groups.
Although we did not demonstrate the yearly change of
respiratory function parameters is related to the prognosis
of CPFE and IPF alone, separating CPFE from IPF patients
may be necessary to make the role of respiratory functions
clear in the prognosis of IPF.0 4 8 12 16
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Figure 4 KaplaneMeier survival curves were drawn for CPFE
and IPF-alone patients whose respiratory functions had been
monitored at least twice with at least a one-year interval.
There was no significant difference in the duration of survival
between patients with CPFE (nZ 26, thick line) and IPF alone
(nZ 33, thin line) (pZ 0.212).
Pulmonary fibrosis and coexistent emphysema 1215In conclusion, we are the first to show that the yearly
decrease in VC and TLC of patients with CPFE is less than
that of patients with IPF alone. In CPFE patients, initial
DLco was significantly less than in patients with IPF alone,
but the decrease in DLco per year thereafter was modest
compared with that of patients with IPF alone. Determining
whether emphysema is coexistent in ‘‘IPF’’ is important for
correct interpretation of the results of respiratory function
tests and for accurate prediction of prognosis. Further
studies to elucidate the roles of gas-exchange and venti-
latory impairments as prognostic factors are warranted.
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